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Background: Continuing efforts in development of non-invasive prenatal genetic tests have
focused on the isolation of fetal nucleated red blood cells (NRBCs) from maternal blood for
decades. Because no fetal cell-speciﬁc antibody has been described so far, the present study
focused on the development of monoclonal antibodies (mAbs) to antigens that are expressed
exclusively on fetal NRBCs.
Methods: Mice were immunized with fetal erythroid cell membranes and hybridomas screened
for Abs using a multi-parameter ﬂuorescence-activated cell sorting (FACS). Selected mAbs were
evaluated by comparative FACS analysis involving Abs known to bind erythroid cell surface
markers (CD71, CD36, CD34), antigen-i, galactose, or glycophorin-A (GPA). Speciﬁcity was further
conﬁrmed by extensive immunohistological and immunocytological analyses of NRBCs from
umbilical cord blood and fetal and adult cells from liver, bone marrow, peripheral blood, and
lymphoid tissues.
Results: Screening of 690 hybridomas yielded three clones of which Abs from 4B8 and 4B9 clones
demonstrated the desired speciﬁcity for a novel antigenic structure expressed on fetal
erythroblast cell membranes. The antigenic structure identiﬁed is different from known surface
markers (CD36, CD71, GPA, antigen-i, and galactose), and is not present on circulating adult
erythroid cells, except for occasional detectability in adult bone marrow cells.lsevier Inc.
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H (German Collection of Microorganisms and Cell Cultures); MNCs, Mononuclear cells; FCS,
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Table 1 – Overview of number and prove
Tissue Total
Yolk sac 4
Fetal liver 8
Fetal bone marrow 4
Fetal blood 14
Umbilical cord blood 35
Fetal lymph node 14
Adult bone marrow 32
Adult liver 8
Adult peripheral blood 5
Adult lymph node 8
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 2 7 0 0 – 2 7 0 7 2701Conclusions:The new mAbs speciﬁcally bind the same or highly overlapping epitopes of a surface
antigen that is almost exclusively expressed on fetal erythroid cells. The high speciﬁcity of the
mAbs should facilitate development of simple methods for reliable isolation of fetal NRBCs and
their use in non-invasive prenatal diagnosis of fetal genetic status.
& 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Development of a reliable non-invasive alternative to prenatal
diagnostic procedures such as amniocentesis and chorionic villous
sampling used to detect fetal aneuploidies has been the goal of
numerous scientiﬁc groups. Aside from fetal nucleated red blood cells
(NRBC, also known as erythroblasts), trophoblasts [1,2] or fetal cell-
free DNA [3,4] have also been considered as objects for prenatal
diagnostics out of maternal blood. Methods used to enrich the rare
fetal NRBCs (about 1–8 fetal erythroblasts in 2 mLmaternal blood) are
amongst others combinations of cell sorting with magnetic particles
or ﬂow cytometry [5,6], density gradient centrifugation [7], selective
cell lysis [8], or depletion of unwanted cell populations (5). Cells from
very early developmental stages such as the colony forming deﬁnitive
erythroid progenitors (BFU-E) can be isolated from umbilical cord
blood using CD34 [9]. To enrich and identify erythroid cells from later
developmental stages, surface markers such as CD71 [10], glycophorin
A [11], CD36 [12] and intracellularly expressed hemoglobins have
been used [13,14].
Since Bianchi et al. [15] ﬁrst used antibodies to CD71 to isolate
fetal erythroid cells from maternal peripheral blood, the transfer-
rin receptor has become one of the most frequently used selection
markers [16]. Soybean agglutinin (SBA) has also been used to
isolate fetal erythroid precursors from blood of pregnant women
because the formation of membrane galactose is closely linked to
the development and maturation of erythroid precursor cells [17].
The fetal origin of the isolated cells can be proved by PCR-
ampliﬁcation of Y-chromosome-speciﬁc sequences [18], by ﬂuores-
cence in situ hybridization (FISH), by detecting ε- and γ-globin, or by
comparing DNA-polymorphisms with STR (short tandem repeats)-
markers from mother and child [19]. However, the Y-chromosome
detection method excludes the examination of pregnancies with a
female fetus, fetal globins are also formed in adults that have
hematologic diseases, and STR-markers do not always detect a
DNA-polymorphism between mother and child [20].
The identiﬁcation and isolation of fetal cells is still difﬁcult
because no surface antigens are known that are exclusivelynance of embryonic, fet
number of samplesexpressed on these cells. Therefore, the aim of this study was
the development of a fetal cell-speciﬁc monoclonal antibody
which enables the characterization of fetal erythroid cells as well
as their differentiation and isolation from adult erythroid blood
cells and leucocytes.Materials and methods
Samples
To test the speciﬁcity of the new mAbs for fetal erythroid cells,
cytospin preparations with mononuclear cells from term umbili-
cal cord blood, blood smears with fetal blood, fetal and adult bone
marrow, and frozen sections of yolk sac tissue, fetal and adult
liver, fetal and adult lymphatic tissue were investigated (Table 1).
The samples were provided, stained and analyzed by Professor
Reza Parwaresch at the Institute for Hematopathology of the
University of Kiel, Germany. Umbilical cord blood samples that
were used for ﬂow cytometric tests were provided by the
Paracelsius Clinic birth unit in Langenhagen, Germany. Samples
were collected after informed consents were obtained from blood
and tissue donors.
Cell lines K-562 and KMOE-2 were purchased from DSMZ
(Deutsche Sammlung vonMikroorganismen und Zellkulturen GmbH).
Development of monoclonal antibodies: Antigen
preparation and immunizaton
The isolation of fetal erythroid cell membranes used for immu-
nization was performed by Genelab (Gelsenkirchen, Germany).
Erythroid cord blood cells from term pregnancies were isolated
based on differential expression of known surface antigens using
multi-parameter FACS. Isolated cells were CD71+ and antigen i+
and negative for CD3, CD14, CD19, and CD45. Those cells were
lysed and the cell membranes separated from the nuclei by
centrifugation. Five mice were immunized with cell membranesal, and adult tissue samples.
Gestation week Analyses performed
6 and 8 Microscope
6, 8, 20 and 30–38 Microscope
10, 20 and 30–38 Microscope
6, 8, 20 and 30–38 Microscope
38–40 FACS
6, 8, 20 and 30–38 Microscope
N/A Microscope
N/A Microscope
N/A FACS
N/A Microscope
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done according to a standard protocol [21]. Next, spleen cells from
the immunized mice were fused with the mouse myeloma cell line
NSO [22]. The ﬁve fusions were divided into 2–3 portions each
and stored in liquid nitrogen for further investigation.
Hybridoma cloning and antibody puriﬁcation
Selection and cloning of antibody producing hybridomas were
performed by Labsoft AG (Halle/Saale, Germany) using standard
methods. The cell culture supernatants from positive clones were
then sent to AdnaGen AG (Langenhagen, Germany) for screening and
selection of fetal erythroid cell-speciﬁc reactivity using a speciﬁcally
established multi-parameter FACS approach described below. Hybri-
domas producing antibody of desired speciﬁcity were then exten-
sively sub-cloned using two sequential 12-steps limiting dilution
processes. Finally, larger scale hybridoma cell cultures were grown
from single cell clones and puriﬁed antibody was produced using a
standard protein-G afﬁnity column chromatography. Where indi-
cated, puriﬁed antibodies were used unlabeled or after labeling with
biotin and/or other detection moieties.
Isolation and processing of blood mononuclear cell
fraction
Mononuclear cell (MNC) fractions from umbilical cord blood and
bone marrow were isolated by density gradient centrifugation on
Ficoll-Paque 1.077 g/mL according to the manufacturer's instruc-
tions (Amersham Biosciences). For preservation, 107 cells were
suspended in 1 mL fetal calf serum (FCS; Gibco) and 500 mL
freezing medium was added. The freezing medium consisted of
10% DMSO (dimethylsulfoxide) and 40% FCS. After 24 h incubation
at 80 1C, the cells were then placed in liquid nitrogen for long-
term storage.
Prior to use, the cells were thawed at 37 1C and resuspended in
about 50 mL Medium A (Iscove's Modiﬁed Dulbecco's Medium
with 10% FCS and 20 U/mL DNAse I) that was added drop-wise
(10 mL). After centrifugation the cell pellet was resuspended in
10 mL medium B (Iscove's Modiﬁed Dulbecco's Medium with 10%
FCS) and centrifuged again. Supernatant was removed and cells
resuspended in the remaining medium.
Antibody screening by multi-parameter ﬂow cytometry
To screen and select for antibodies that speciﬁcally bind surface
antigens of fetal erythroid cells, a six-parameter ﬂuorescence-
activated cell sorting (FACS) method was developed. This multi-
marker and high throughput approach facilitated reproducible
screening of large numbers of culture supernatants of antibody-
producing hybridomas. The components of the system included
four ﬂuorescence channels combined with determinations of
forward (FSC) and side (SSC) scatters. Allophycocyanin (APC)-
labeled anti-CD45 (CD45-APC), phycoerythrin (PE)-labeled anti-
CD71 (CD71-PE), and the DNA dye LDS 751 were used to
simultaneously identify leucocytes, erythroid, and nucleated cells,
while the sixth channel set for detection of ﬂuorescein isothio-
cyanate (FITC) was used for detection of the new antibodies under
investigation.
Hybridoma supernatants were screened on cryopreserved or
freshly isolated MNCs using direct or indirect immunoﬂuorescencestaining. Cell count and viability (not described) were always
checked prior to staining and isotype controls of all antibodies
were determined. Brieﬂy, 2105 cells in 15 mL PBS (phosphate-
buffered saline), pH 7.2, containing 0.5% bovine serum albumin
(BSA) was placed in 5 mL-tubes and mixed with FC receptor (FcR)
blocking reagent (Miltenyi Biotech). Cell culture supernatant
(35 mL) from antibody-producing hybridomas was then added to
the cell suspension, mixed, and incubated for 10 min at room
temperature (RT). The cells were washed with 3 mL PBS buffer
and centrifuged for 5 min at 400 g and 4 1C. The supernatant
was vacuumed off to about 50 mL and the cells were resuspended
in the remaining buffer. For indirect staining, the primary
antibody-labeled cell suspension was next incubated with a
secondary anti-species antibody labeled with FITC. In a third step,
the labeled cells were incubated with ﬂuorescence labeled anti-
bodies against CD71 (anti-CD71-PE), and CD45 (anti-CD45-APC),
and with the nucleus dye LDS 751. All incubation steps with
ﬂuorescent dyes have been performed for 10 min in the dark.
After the last wash, the cells were ﬁxed by re-suspension in
300 mL 1Cellﬁx solution (BD Biosciences) and stored at 4 1C in
the dark until analysis with a FACSCalibur (BD Biosciences). The
data were collected and evaluated with the CellQuest Pro soft-
ware (BD Biosciences).
Immunostaining, immunocytochemical, and
immunoﬂuoresence microscopy
Immunostaining of various cells and tissue sections was per-
formed using the commercially available alkaline phosphatase
anti-alkaline phosphatase (APAAP) kit (Universal APAAP kit, Dako
Cytomation). The preparations were incubated for 30 min at RT
with the undiluted antibody under evaluation. After washing in
tris-buffered saline (TBS, pH 7.4), the preparations were incubated
with a secondary rabbit anti-mouse IgM antibody diluted 1:25 in
TBS containing 10% human serum for 30 min at RT. This was then
followed by washing and incubation with the APAAP-complex
diluted 1:50 in TBS containing 10% human AB-serum (blood group
antigens AB) for 30 min. The washing and incubation with the
secondary antibody and the APAAP complex was repeated twice
as above. The preparations were ﬁnally developed with Neufuch-
sin substrate solution for 10–20 min at RT, washed with tap water,
and counterstained with Mayers Hemalaun. The preparations
were sealed with Kaiser Glycerol gelatin (Merck) and analyzed
with a universal microscope (Axioplan 2, Carl Zeiss).
Immunostaining was also performed using the UltraVision-HRP
method (UltraVision™, LabVision Corporation). Brieﬂy, endogen-
ous peroxidases were blocked for 10 min at RT with peroxidase
blocking reagent (Dako Cytomation), the sections washed twice
with TBS containing 0.05% Tween-20, and incubated for 10 min
with Ultra V Block. The sections were then incubated with the
undiluted antibody to be tested for 30 min at RT. After washing as
above, the biotinylated goat secondary antibody detection reagent
was added. The reaction was developed using the streptavidin-
horseradish peroxidase (HRPO) conjugate and the chromogenic
ACE+ substrate system (Dako Cytomation). Finally, the reaction
was stopped by incubation with aqua dest. Counter staining was
performed with Mayers Hemalaun for 2 min and the “blueing”
was done under ﬂowing tap water.
For double immunoﬂuorescence staining with anti-GPA and
new mAbs under investigation, ﬁxed and dried cytospins or
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mouse anti-GPA Ab appropriately diluted in PBS containing 1%
BSA. After washing with PBS, the preparations incubated as above
with goat anti-mouse IgG Alexa Fluor 488 conjugate (Molecular
Probes). After a second washing, the GPA tagged preparations
were sequentially incubated as above with undiluted new mAb
for 60 min (mouse IgM isotype) to be tested, and then similarly
with goat anti-mouse IgM-Alexa 594 conjugate (Molecular
Probes). This was followed by 3 min staining of cell nuclei with
DAPI (Molecular Probes) appropriately diluted in PBS. Prepara-
tions were viewed with a universal microscope (Axioplan 2)
equipped with appropriate ﬁlters and documented with the
digital camera system (MetaFluor Imaging System; Visitron
Systems GmbH).Results
Identiﬁcation of fetal cell-speciﬁc antibody-producing
hybridoma clones 4B8, 4B9 AND 5D10
Establishment of the multi-parameter FACS of differentially
labeled MNCs from umbilical cord blood allowed reproducible
screening of large numbers of hybridomas by enabling simulta-
neous identiﬁcation of erythroid cells, differentiation of leuco-
cytes from enucleated erythrocytes, and determination of binding
speciﬁcity of the new Abs in a single step process. Scattered light
characteristics of cells with different size (FSC) and granularity
(SSC) was used to gate for the target cells (Fig. 1A; region R1).
Erythroid target cells were expected to express the marker CD71
(Fig. 1B; region R2). Leukocytes were excluded with CD45 (Fig. 1C;
region R3) and nucleated cells were detected with the DNA-dyeFig. 1 – FACS-based pre-selection of erythroid cells for antibody scr
characteristics based on FSC and SSC. R1 gates lymphocyte and ery
nucleated cells. (1C) CD45-positive cells were gated in R3 and excluLDS 751. The target cells (NRBCs) were identiﬁed by logically
linking R1+R2R3. A total of 690 cell culture supernatants from
four immunizations were screened for antibodies that speciﬁcally
bound NRBCs from umbilical cord blood. The screening resulted in
the identiﬁcation of three antibody-producing hybridoma clones
4B8, 4B9, and 5D10 (Fig. 1D–F). These novel Abs bound nucleated
cells that were CD71-positive and CD45-negative (upper right
quadrant). Antibodies 4B8 and 4B9 bound ∼72–82% of the CD71-
postive cells while Ab 5D10 detected ∼35%.MABs 4B8 AND 4B9 show no reactivity to adult blood
group antigens and speciﬁc cell lines
The new mAbs 4B8, 4B9, and 5D10 are of the IgM isotype. By
competitive binding analysis, mAbs 4B8 and 4B9 were found to
bind the same or highly overlapping epitopes of a surface antigen
on fetal NRBCs, while mAb 5D10 detected a different determinant
and also showed some reactivity with monocytes (data not
shown).
The new mAbs did not bind adult erythrocytes or blood group
antigens as pre-incubation of the antibodies with increasing numbers
of AB adult erythrocytes did not reduce their reactivity against
umbilical cord erythroblasts. As negative and positive control the
binding of anti-CD71 and anti-GPA to fetal NRBCs was tested after
pre-incubation with adult erythrocytes, respectively. In accordance to
the known surface expression a pre-incubation of anti-GPA with adult
erythrocytes completely removed its binding capacity to cord blood
cells, while similar to mAbs 4B8, 4B9, and 5D10, pre-incubation of the
anti-CD71 did not block its anti-cord blood erythroblast reactivity
(data not shown).eening and detection of hybridoma clones. (1A) Scattered light
throid precursor populations. (1B) R2 gates CD71-positive
ded. (1D–1F) Detection of antibody clones 4B8, 4B9, and 5D10.
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not bind to the leukemia cell line K-562 and the erythroid cell line
KOME-2 which exhibit distinct developmental stages of erythroid
cells and thus, a speciﬁc biomarker expression pattern [23,24].
This was revealed by comparative FACS analysis of the new mAbs
versus binding of commercial Abs to known surface markers such
as CD71, CD36, GPA, galactose, and CD45. MNCs from umbilical
cord blood served as positive control (data not shown). Further
speciﬁcity studies have primarily been done with mAb 4B9.
Analyses of embryonic, fetal, and adult tissues further
demonstrate speciﬁcity of 4B9
An extensive summary of histological and FACS comparative
analyses of mAb 4B9 for its reactivity against various fetal and
adult tissues is depicted in Tables 2 and 3, and Figs. 2–4.
Ab 4B9 tested positive against all examined embryonic and fetal
tissues as well as fetal blood samples (Table 2). Immunohisto-
chemical staining of frozen tissues from yolk sac showed binding
of mAb 4B9 to the embryonic primitive erythroblasts found in
yolk sac blood islands, but no reaction occurred with embryonic
stem cells (hemocytoblasts) (data not shown).
Blood cells from fetal liver preparations of gestation weeks 6, 8,
20, and 30 were analyzed to study the early expression of 4B9-
antigen in fetal development. Fig. 2A exemplarily shows the
results of the stained frozen fetal liver sections of the 20th
gestation week. The collections of GPA- and 4B9-positive cells
are blood forming foci with erythroid precursors. The negative
areas are formed by the liver cells. Fig. 2A shows 4B9-positive,
nucleated cells (red ﬂuorescence) that also expressed the ery-
throid marker GPA (green ﬂuorescence). In addition, hepatocytes
were detected that did not express either of these antigens (arrow
head). Fetal erythroblasts were 4B9-positive in all samples of the
different gestational weeks tested.
Fig. 2B and C represent results of fetal bone marrow analysis
showing GPA-positive and 4B9-positive fetal NRBCs. Microscopic
analysis of fetal blood samples stained with anti-4B9 and anti-
GPA are shown in Fig. 3A and B.
To prove that the 4B9-antigen is exclusively expressed on fetal
cells, adult tissues have been stained with anti-GPA and anti-4B9 forTable 2 – Summary of histologic and cytological analyses perform
Embryonic /fetal tissue NRBCsa Reticulocytes/erythro
4B9 GPA 4B9 GP
Yolk sac + +++ – ++
Liver + +++ (+) ++
Bone marrow + +++ (+) ++
Peripheral blood + +++ (+) ++
Umbilical cord blood + +++ (+) ++
Lymph node – – – –
Adult tissue 4B9 GPA 4B9 GP
Bone marrow [] +++ – ++
Liver – ++ - ++
Peripheral blood – +++ – ++
Lymph node – – – –
a Normoblasts, euchromatic/polychromatic/basophilic erythroblasts, proerythr
Intensity of marker expression; (+) 4B9-expression was detectable in all sa
marrow samples about 5–10% of the erythroblasts were 4B9-positive.microscopic analysis (Table 2, Fig. 4). Adult liver cells, lymphatic cells,
peripheral blood cells (data not shown) and bone marrow cells
showed no reaction with mAb 4B9. However, there was a detectable
reactivity with the 4B9 Ab in 1 of 32 (3%) adult bone marrow
samples (Fig. 4C). In this particular sample about 5–10% of the
erythroblasts, in fact euchromatic erythroblasts, were 4B9-positive.
Through further FACS and microscopic analyses we compared the
occurrence of the 4B9-antigen during ontogeny to that of GPA
(Table 3). The 4B9-antigen is expressed during embryonic and fetal
erythropoiesis as deﬁned according to the published data concerning
other well-known erythroid markers like CD36, CD71, and terminal
α- or β-N-acetylgalactosamine, but – with one exception – not in
adult erythropoiesis. GPA is expressed on all NRBCs, reticulocytes
and erythrocytes formed in embryonic, fetal, and adult tissues.Discussion
Despite signiﬁcant progress in downstream chromosomal and
genetic testing, unavailability of a highly speciﬁc anti-fetal erythro-
blast antibody has remained a major limiting factor to successful
development of non-invasive prenatal diagnostic tests. To address
these unmet analytical and clinical needs, we here described
development and characterization of mAbs that speciﬁcally bind to
surface epitopes distinctively expressed on plasma membranes of
fetal erythroblasts. Development of a six-parameter FACS assay
facilitated screening of large numbers of Ab-producing clones.
Further test results showed that Abs from the suitable clones 4B8
and 4B9 appeared to detect a single or highly overlapping epitopes
of a fetal-erythroblast speciﬁc surface antigen.
The cytological and histological data on the characterization of the
4B9-antigen expression indicate that this surface structure seems to
be closely linked to the development of the body's blood forming
system (Table 3). The results of the fetal tissue analyses (fetal liver,
fetal bone marrow, and fetal blood) showed that the 4B9-antigen is
present on normoblasts, euchromatic, polychromatic, and basophilic
erythroblasts, on pro-erythroblast and weakly on most reticulocytes
and erythrocytes (Table 2, Figs. 2 and 3). No reaction was detectable
with fetal hemolymphatic cells or fetal myeloid cells. Accordingly,
mAb 4B9 demonstrated binding to primitive erythroblasts found ined with anti-4B9 and anti-GPA.
cytes Macrophages, dendritic cells, T- and B-lymphocytes
A 4B9 GPA
+ – –
+ – –
+ – –
+ – –
+ – –
– –
A 4B9 GPA
+ – –
+ – –
– –
oblasts; NRBCs: Nucleated red blood cells; –No antigen expression;+/+++
mples but not on all cells of a sub-population; [] In 1 of 32 adult bone
Table 3 – B9-antigen expression during ontogeny.
Marker Embryonic erythropoiesis Fetal erythropoiesis Adult erythropoiesis
Yolk sac primitive NRBCs Fetal liver NRBCs Fetal BM NRBCs Adult BM NRBCs
CD71 (+) ++ ++ ++
CD36 – ++ ++ ++
GalNAca ? ++ ++ ++
Glycophorin A +++ +++ +++ +++
4B9 + + + –
a GalNAc: Terminal α- or β-N-acetylgalactosamine (detected with SBA); yolk sac: expression of markers CD71, CD36, and GalNAc according to literature;?
No data found in the literature; (+) marker expression low or undetectable; +/++/+++ increasing intensity of antigen expression.
Fig. 2 – Immunoﬂuorescence and immunohistochemical staining performed on fetal liver frozen sections and fetal bone marrow
cells, gestation week 20. (2A) Fetal liver sections: 4B9-positive fetal NRBCs (arrow, red ﬂuorescence) were also GPA-positive (green);
nucleus staining (blue); hepatocytes (arrow head). Overlapping red and green ﬂuorescence appears yellow. (2B) Fetal bone marrow
cells: APAAP-staining with anti-GPA and (2C) with anti-4B9. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 3 – Immunoﬂuorescence staining performed on fetal peripheral blood cells, gestation week 36. (3A) GPA-positive (green
ﬂuorescence) and 4B9-positive (red ﬂuorescence) non-nucleated erythrocytes and reticulocytes, 400 . (3B) GPA- and 4B9-positive
nucleated erythroid precursor cell (zoom). (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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stem cells (hemocytoblasts).
An expression of the 4B9-antigen was seen on all erythroblast
stages of embryonic blood formation in the yolk sac. In umbilical
cord blood, 4B9-antigen is expressed on all morphologically
identiﬁable stages of fetal erythropoiesis: pro-erythroblasts,
nucleated erythroid precursors, reticulocytes and erythrocytes.
The 4B9-antigen was only found on erythroid precursors in one
adult bone marrow sample but was not detectable in adult
peripheral blood.The results of adsorption studies with adult AB+erythrocytes
demonstrated that 4B9 mAb does not bind surface structures
expressed on the strongly glycosylated adult erythrocytes. The
latter strongly supports the notion that the 4B9 Ab-targeted
antigen is unlikely to be one of the main blood group antigens
such as antigens i and I, GPA, and membrane-bound galactose
chains detected by the binding of soybean agglutinin [25,26].
CD36, the thrombospondin receptor, was eliminated as a possible
4B9-antigen because it is expressed on both fetal as well as adult
monocytes. Similarly, the possibility of 4B9 mAb recognizing the
Fig. 4 – APAAP-staining performed on adult bone marrow cells. (4A) Anti-4B9 is negative for adult erythroid bone marrow cells and
leukocytes; 400 . (4B) NRBCs, mature erythrocytes or reticulocytes are positive for marker GPA; 400 . (4C) One 4B9-positive
adult bone marrow cell with cytoplasmic staining (arrow); 400 . Arrows head: non-nucleated erythrocytes/reticulocytes; arrow:
erythroblasts.
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expressed on both fetal and adult erythroid cells. In addition,
the transferrin receptor, CD71, was excluded as the potential 4B9-
antigen as antibodies speciﬁc to CD71 did not compete with 4B9
Ab for cell surface binding and as importantly, 4B9 Ab did not
bind to cell lines such as the leukemia cell line K-562, which
strongly expresses CD71 [27]. Furthermore, the earliest detectable
4B9-antigen was seen at the pro-erythroblast stage while CD71,
according to literature, is already expressed on early CD34-
positive BFU-E [28]. Accordingly, in our FACS analysis, a subpo-
pulation of CD34 and CD71 double positive cells was found, but
no CD34 and 4B9 double positive population was detected.
By immunoﬂuorescence staining, the 4B9 antigen appeared to
have a speciﬁc dot- or drop-like distribution on the surface of
fetal erythroid cells (Fig. 3B), which is quite similar to the
expression pattern CD71 demonstrated in our microscopic ana-
lyses (data not shown). Although CD71 can be eliminated as the
targeted antigen, a comparison of the expression patterns might
allow conclusions on the structure of the 4B9 antigen. Because
CD71 is a highly glycosylated transmembrane receptor [29] with
similar immunoﬂuorescence expression patterns to that of 4B9,
one might postulate that the 4B9 antigen is also a transmembrane
molecule with possibly similar functions to CD71 in cell prolifera-
tion and differentiation.
Properties of erythroid cells are used for diagnosing hematolo-
gic diseases [30], but also for prenatal testing of non-hematologic
disorders [20], namely early analyses of aneuploidies (e.g. triso-
mies 13, 18, and 21) or gene defects (e.g. cystic ﬁbrosis, dystro-
phia). An ultimate goal is to develop reliable analytical methods
that are safe for mother and fetus to replace invasive intervention
such as the amniocentesis [2,9]. Fetal NRBCs are the most suitable
cells that have been increasingly targeted for establishment of
non-invasive prenatal diagnostic tests [31]. The molecular struc-
ture of the 4B9-antigen still has to be determined however, its
potential to detect rare fetal cells in the blood of pregnant women
has been demonstrated by its speciﬁcity for fetal erythroblast. The
antigenic structure speciﬁcally targeted by 4B9 mAb is expressed
on fetal primitive NRBCs as well as on fetal deﬁnitive erythro-
blasts, but not on adult peripheral blood cells. The speciﬁcity of
this novel mAb to primitive fetal cells should enable future
developments of simple fetal isolation strategies important to
eventual development of reliable non-invasive prenatal diagnostic
strategies. This remains to be shown in further studies.
In summary, the 4B9-antigen is an unknown membrane-bound
structure that is almost exclusively formed on fetal erythroid cellsand that is expressed during embryonic and fetal erythropoiesis.
In adults, it was detectable only in one exceptional case in adult
bone marrow but not in peripheral blood. Due to the speciﬁc
expression of the 4B9-antigen this novel marker seems to be
suited to speciﬁcally characterize and identify fetal erythroid cells
and aid in their isolation from maternal blood.Conﬂict of interest
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